Bile acids are physiological detergents that generate bile flow and facilitate intestine absorption and transport of lipids, nutrients and vitamins. Bile acids also are signaling molecules and inflammatory agents that rapidly activate nuclear receptors and a complex network of cell signaling pathways that regulate lipid and glucose metabolism. Despite intense research in recent years, the molecular mechanism of bile acid feedback inhibition of bile acid synthesis remains obscure. It is thought that bile acids activate a nuclear receptor, farnesoid X receptor (FXR) that induces small heterodimer partner (SHP), which inhibits transcription of the CYP7A1 gene encoding cholesterol 71-hydroxylase (CYP7A1), the first and rate-limiting enzyme in bile acid synthesis in the liver. Recent studies have discovered a FXR induced intestinal hormone, fibroblast growth factor 15 (FGF15) (or FGF19 in human) that activates FGF receptor 4 (FGFR4) signaling in mouse liver to inhibit bile acid synthesis. However, the mechanism by which the FXR/FGF19/FGFR4 signaling pathway inhibits CYP7A1 remains unknown. The central hypothesis is that bile acids and FXR regulate CYP7A1 gene expression via activation of an intricate network of nuclear receptor cell signaling pathways that regulate CYP7A1 gene transcription, and that micro RNAs may play a role in post-transcriptional regulation of the human CYP7A1 gene.
Three specific aims are: 1. Study the mechanism of FGF19/FGFR4 regulation of CYP7A1 and bile acid synthesis in human hepatocytes. 2. Study microRNA regulation of CYP7A1 and bile acid synthesis in human hepatocytes. 3. Study the role of CYP7A1 in control of hepatic inflammation and lipid metabolism. The overall objective of this study is to elucidate the molecular mechanism of bile acid-activated nuclear receptor and cell signaling pathways in regulation of CYP7A1 and bile acid synthesis in liver health and diseases. Dysregulation of bile acid metabolism causes cholestatic liver injury and contributes to liver cirrhosis, steatosis, dyslipidemia, diabetes, obesity, and atherosclerosis. Drugs targeting to nuclear receptor and signaling pathways, and miRNA antagomirs may be developed for treating metabolic liver diseases.

Public Health Relevance

Bile acids are physiological lipid molecules required for absorption of nutrients, transport of lipid and steroids, and disposal of toxic and xenobiotics. Bile acids also are signaling molecules that activate nuclear receptors and cell signaling pathways to regulate lipid and glucose homeostasis. Bile acid synthesis is tightly regulated at the first and rate-limiting enzyme CYP7A1 by a bile acid feedback mechanism. The molecular mechanism of bile acid feedback inhibition of CYP7A1 remains unclear. The proposed specific aims are designed to elucidate the molecular mechanism of bile acid-activated nuclear receptor FXR signaling in transcription and post- transcriptional regulation of the human CYP7A1 gene. The project is highly relevant to prevention and treatment of hepatobiliary diseases, diabetes, obesity and atherosclerosis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK044442-15
Application #
8054227
Study Section
Hepatobiliary Pathophysiology Study Section (HBPP)
Program Officer
Sherker, Averell H
Project Start
1997-09-30
Project End
2014-05-31
Budget Start
2011-06-01
Budget End
2012-05-31
Support Year
15
Fiscal Year
2011
Total Cost
$316,355
Indirect Cost
Name
Northeast Ohio Medical University
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
077779882
City
Rootstown
State
OH
Country
United States
Zip Code
44272
Chiang, John Y L; Ferrell, Jessica M (2018) Bile Acid Metabolism in Liver Pathobiology. Gene Expr 18:71-87
Donepudi, Ajay C; Ferrell, Jessica M; Boehme, Shannon et al. (2018) Deficiency of cholesterol 7?-hydroxylase in bile acid synthesis exacerbates alcohol-induced liver injury in mice. Hepatol Commun 2:99-112
Pathak, Preeti; Xie, Cen; Nichols, Robert G et al. (2018) Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism. Hepatology 68:1574-1588
Chiang, John Y L (2017) Linking Sex Differences in Non-Alcoholic Fatty Liver Disease to Bile Acid Signaling, Gut Microbiota, and High Fat Diet. Am J Pathol 187:1658-1659
Chiang, John Y L (2017) Linking long noncoding RNA to control bile acid signaling and cholestatic liver fibrosis. Hepatology 66:1032-1035
Chiang, John Y L; Pathak, Preeti; Liu, Hailiang et al. (2017) Intestinal Farnesoid X Receptor and Takeda G Protein Couple Receptor 5 Signaling in Metabolic Regulation. Dig Dis 35:241-245
Chiang, John Y L (2017) Bile acid metabolism and signaling in liver disease and therapy. Liver Res 1:3-9
Pathak, Preeti; Liu, Hailiang; Boehme, Shannon et al. (2017) Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism. J Biol Chem 292:11055-11069
Donepudi, Ajay C; Boehme, Shannon; Li, Feng et al. (2017) G-protein-coupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis in mice. Hepatology 65:813-827
Chiang, John Y L (2017) Targeting bile acids and lipotoxicity for NASH treatment. Hepatol Commun 1:1002-1004

Showing the most recent 10 out of 88 publications